Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), which catalyze breakdown of the neurotransmitter acetylcholine in cholinergic synapses, are currently the most viable therapeutic targets for symptomatic treatment of AD. The gene discussed is ACHE; the disease is Alzheimer disease.